Cargando…

Second malignancies among older patients with classical myeloproliferative neoplasms treated with hydroxyurea

Patients with classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET), and primary and secondary myelofibrosis (MF), are known to have an increased risk of second malignancies (SMs). Hydroxyurea (HU) is a guidel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Rong, Shallis, Rory M., Stempel, Jessica M., Huntington, Scott F., Zeidan, Amer M., Gore, Steven D., Ma, Xiaomei, Podoltsev, Nikolai A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Health Services and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989521/ https://www.ncbi.nlm.nih.gov/pubmed/35917456 http://dx.doi.org/10.1182/bloodadvances.2022008259

Ejemplares similares

Older patients with chronic myeloid leukemia face suboptimal molecular testing and tyrosine kinase inhibitor adherence
por: Shallis, Rory M., et al.
Publicado: (2023)

Changes in Multiple Myeloma Treatment Patterns during the Early COVID-19 Pandemic Period
por: Neparidze, Natalia, et al.
Publicado: (2021)

Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
por: Podoltsev, Nikolai A., et al.
Publicado: (2023)

Prevalence of frailty and its association with clinical outcomes in myeloproliferative neoplasms: a population-based study
por: Bankar, Aniket, et al.
Publicado: (2023)

Changes in multiple myeloma treatment patterns during the early COVID-19 pandemic period
por: Neparidze, Natalia, et al.
Publicado: (2022)

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States
por: Shallis, Rory M., et al.
Publicado: (2021)

Most adults with severe HbSC disease are not treated with hydroxyurea
por: Ghunney, William Kwesi, et al.
Publicado: (2023)

Survival of mantle cell lymphoma in the era of Bruton tyrosine kinase inhibitors: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2022)

Treatment patterns and real-world effectiveness of rituximab maintenance in older patients with mantle cell lymphoma: a population-based analysis
por: Di, Mengyang, et al.
Publicado: (2023)

Practice patterns and real-life outcomes for patients with acute promyelocytic leukemia in the United States
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2022)

Emerging agents and regimens for polycythemia vera and essential thrombocythemia
por: Shallis, Rory M., et al.
Publicado: (2021)

More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes
por: Shallis, Rory M., et al.
Publicado: (2018)

Targeting myeloid cells to prevent recurrent stroke in general population: the lesson of hydroxyurea in myeloproliferative neoplasms
por: Barbui, Tiziano, et al.
Publicado: (2018)

Risk of myeloid neoplasms after radiotherapy among older women with localized breast cancer: A population-based study
por: Zeidan, Amer M., et al.
Publicado: (2017)

Incidence and risk factors for second malignancies among patients with myeloproliferative neoplasms
por: Zhang, Yuhui, et al.
Publicado: (2023)

Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates?
por: Zeidan, Amer M., et al.
Publicado: (2018)

Coping in caregivers of patients with hematologic malignancies undergoing hematopoietic stem cell transplantation
por: Amonoo, Hermioni L., et al.
Publicado: (2022)

Outcomes of patients with hematologic malignancies and COVID-19: a report from the ASH Research Collaborative Data Hub
por: Wood, William A., et al.
Publicado: (2020)

Outcomes of breakthrough COVID-19 infections in patients with hematologic malignancies
por: Chien, Kelly S., et al.
Publicado: (2023)

Evolving Therapeutic Strategies for the Classic Philadelphia-Negative Myeloproliferative Neoplasms
por: Kaplan, Jason B., et al.
Publicado: (2016)

Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea
por: Lim, Yoojoo, et al.
Publicado: (2016)

Cytological Diagnosis of Classic Myeloproliferative Neoplasms at the Age of Molecular Biology
por: Combaluzier, Sophie, et al.
Publicado: (2023)

Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review
por: Gavini, Divya R, et al.
Publicado: (2021)

Hydroxyurea-Induced Pneumopathy in a Patient With Myeloproliferative Syndrome
por: Galván, Oriol Plans, et al.
Publicado: (2018)

Epigenetic therapy combinations in acute myeloid leukemia: what are the options?
por: Bewersdorf, Jan Philipp, et al.
Publicado: (2019)

Association Between Ownership of Imaging Equipment and Appropriateness of Staging Positron-Emission Tomography in Non-Hodgkin Lymphoma
por: Huntington, Scott F, et al.
Publicado: (2019)

A Broad Overview of Signaling in Ph-Negative Classic Myeloproliferative Neoplasms
por: Guijarro-Hernández, Ana, et al.
Publicado: (2021)

Myeloproliferative neoplasms
por: Cross, Nick
Publicado: (2019)

Myeloproliferative neoplasms
por: Kiladjian, Jean-Jacques
Publicado: (2018)

Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why?
por: Cumbo, Cosimo, et al.
Publicado: (2022)

Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms
por: Vanni, Daniele, et al.
Publicado: (2022)

Cellular aging is accelerated in the malignant clone of myeloproliferative neoplasms
por: Vieri, Margherita, et al.
Publicado: (2023)

Lifetime medical costs attributable to sickle cell disease among nonelderly individuals with commercial insurance
por: Johnson, Kate M., et al.
Publicado: (2022)

COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals
por: Singh, Ashima, et al.
Publicado: (2021)

Classical Philadelphia-negative myeloproliferative neoplasms: focus on mutations and JAK2 inhibitors
por: Helbig, Grzegorz
Publicado: (2018)

Health following recovery from immune thrombotic thrombocytopenic purpura: the patient’s perspective
por: Kelley, Rachel A., et al.
Publicado: (2022)

Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022)

Preliminary construct validity of patient-reported outcomes to assess chronic pain in adults with sickle cell disease
por: Mucalo, Lana, et al.
Publicado: (2023)

Precancer and cancer-associated depression and anxiety among older adults with blood cancers in the United States
por: Kuczmarski, Thomas M., et al.
Publicado: (2022)

Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease
por: Hankins, J. S, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0nge4b3aej2rol59e3khcao1ms